Last reviewed · How we verify

Atopiclair Nonsteroidal Cream

Wake Forest University Health Sciences · FDA-approved active Small molecule Quality 2/100

Atopiclair Nonsteroidal Cream is a Small molecule drug developed by Wake Forest University Health Sciences. It is currently FDA-approved. Also known as: MAS063DP.

At a glance

Generic nameAtopiclair Nonsteroidal Cream
Also known asMAS063DP
SponsorWake Forest University Health Sciences
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Atopiclair Nonsteroidal Cream

What is Atopiclair Nonsteroidal Cream?

Atopiclair Nonsteroidal Cream is a Small molecule drug developed by Wake Forest University Health Sciences.

Who makes Atopiclair Nonsteroidal Cream?

Atopiclair Nonsteroidal Cream is developed and marketed by Wake Forest University Health Sciences (see full Wake Forest University Health Sciences pipeline at /company/wake-forest-university-health-sciences).

Is Atopiclair Nonsteroidal Cream also known as anything else?

Atopiclair Nonsteroidal Cream is also known as MAS063DP.

What development phase is Atopiclair Nonsteroidal Cream in?

Atopiclair Nonsteroidal Cream is FDA-approved (marketed).

Related